Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

Radiofrequency Ablation for the Treatment of Recurrent or Oligometastatic Parathyroid Cancer

Trial Status: active

This clinical trial tests the effect of radiofrequency ablation (RFA) in treating patients with parathyroid cancer that has come back after a period of improvement (recurrent) and that has spread from where it first started (primary site) to a limited number of other places in the body (oligometastatic). RFA is a procedure that uses radio waves to heat and destroy abnormal cells. The radio waves travel through electrodes (small devices that carry electricity). RFA may be safe, tolerable, and/or effective in treating patients with recurrent oligometastatic parathyroid cancer.